ixekizumab vs netakimab

NCT01695239 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-comparator-controlled trial in 417 people with active psoriatic arthritis measured ACR20 response at week 24 as its primary endpoint. Both ixekizumab doses clearly outperformed placebo (57.9% and 62.1% vs 30.2%, p<0.001), and the active comparator adalimumab also beat placebo, confirming the trial could detect a true effect.

NCT03598751 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 194 patients. The proportion of patients achieving a validated joint-response measure (ACR20) was overwhelmingly higher with netakimab than placebo, a gap large enough to leave no real doubt about the direction of the effect even though a formal statistical test was not reported in the source used.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT01474512 · Phase 3 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 1,296 participants. Its clinical primary endpoints, sPGA 0/1 and PASI75 at Week 12, were met for both ixekizumab regimens versus placebo, with p<0.001 for each comparison.

NCT03390101 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 213 participants and a clinical psoriasis endpoint (PASI 75) assessed at week 12. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.